Citi Pharma and Xin Weisheng Join Forces to Revolutionize Antibiotic Production in Pakistan
In a strategic move to strengthen Pakistan’s pharmaceutical sector, Citi Pharma has announced a landmark partnership with Chinese firm Xin Weisheng to establish a cutting-edge antibiotic manufacturing facility. The initiative is designed to reduce reliance on imported medicines and enhance national healthcare resilience.
State-of-the-Art Facility Set for 2026 Launch
The facility, slated to begin commercial operations in 2026, will feature:
- Aseptic, automated production lines
- Manufacturing of high-potency antibiotics including meropenem and piperacillin-tazobactam
- Production of both Active Pharmaceutical Ingredients (APIs) and finished dosage forms
This dual-capability approach will allow Pakistan to meet domestic demand while potentially entering export markets.
Technology Transfer and Global Standards
Xin Weisheng will provide:
- Advanced process technology
- Engineering support
- Staff training programs
These contributions aim to ensure the facility meets international quality and safety standards, positioning Pakistan as a competitive player in global pharmaceutical manufacturing.
A Leap Toward Medicine Security
The partnership aligns with Pakistan’s broader goal of achieving self-reliance in essential therapies. By localizing production of critical antibiotics, the country can:
- Safeguard against supply chain disruptions
- Lower healthcare costs
- Improve access to life-saving treatments
“This collaboration is a game-changer for Pakistan’s pharmaceutical landscape,” said a Citi Pharma spokesperson. “It’s not just about manufacturing—it’s about building long-term capacity and resilience.”
+ There are no comments
Add yours